Published: April 27, 2018

Introduction {#sec1}
============

Systemic availability, diminished efficacy, and off-target effects remain challenges to the successful clinical prediction of candidate drugs and contribute to attrition in drug development, highlighting the need for better preclinical tools to model intestinal function *in vitro* ([@bib2], [@bib11], [@bib20]). Oral delivery is the most common method for drug administration, and in addition to absorption and first-pass metabolism, the intestine serves directly as a site of off-target toxicity for compounds such as non-steroidal anti-inflammatory drugs (NSAIDs) ([@bib5]) and chemotherapeutic agents ([@bib3]) and indirectly as a site of drug-drug interactions ([@bib4], [@bib20]). Animal models are frequently used to estimate compound bioavailability; however, species differences can lead to disparity in the expression of metabolic enzymes and transporters, resulting in poor clinical prediction ([@bib11], [@bib17], [@bib20]). Human intestinal slices can provide correct cellular architecture and physiological complexity; however, limited viability *ex vivo* (about 24 hr) and incompatibility with cryopreservation restrict use to short-term studies ([@bib16]). Predominant *in vitro* systems used to study intestinal bioavailability and toxicity include intestinal microsomes and two-dimensional (2D) monolayers. Microsomes are a convenient tool for initial assessment of metabolism, but cannot model cellular level outcomes. Physiological conditions lacking in 2D culture may be improved by microfluidic chip models; however, maintenance of cell-cell and cell-matrix interactions and scale-up for high-throughput applications remain challenging ([@bib40], [@bib41]). Standard 2D monolayers and more recent gut-on-a-chip systems commonly include cell lines originating from colorectal and duodenal tumor tissue ([@bib2], [@bib13]) that may exhibit altered metabolic profiles and expression patterns of xenobiotic-metabolizing enzymes and transporters potentially leading to misrepresentation of the native response ([@bib22], [@bib38]). The colorectal tumor-derived Caco-2 cell line is the most established model to study permeability and predict intestinal absorption. Known limitations of the Caco-2 model include reduced CYP450 activity ([@bib22], [@bib38]), variability with passage number, and inconsistencies between subclones of the cell line ([@bib4]).

Limitations of common *in vitro* models have sparked the development of methods utilizing primary human intestinal cells. Although primary monocultures more closely resemble *in vivo* tissue compared with cell lines ([@bib12], [@bib30]), separation of the epithelium from supportive cells may impair function and limit the ability to study complex cell interactions including interplay with interstitial cells or inflammatory responses. The discovery of organoids to expand primary cells ([@bib23], [@bib39]) or differentiate pluripotent stem cells ([@bib12], [@bib37]) revealed another path to model the intestine *in vitro*. Organoids derived from all regions of the intestinal tract ([@bib36]) can be applied to intestinal research including organ development, disease modeling, and regenerative medicine ([@bib10], [@bib26]), although they may lack *in vivo* organ physiology. Notably, the closed lumen of the organoid structure with inward epithelial orientation makes the apical surface relatively inaccessible for absorption, distribution, metabolism, and excretion (ADME) assays. Approaches to create accessible compartments can require a complex bioreactor setup ([@bib24]) and produce monolayers with non-physiological transepithelial electrical resistance (TEER) ([@bib12], [@bib35]). Cell-seeded engineered three-dimensional (3D) tubular scaffolds have recently been utilized with hollow lumens to promote a more native-like microenvironment ([@bib6]); however, functional characterization is restricted to the apical compartment by geometry, making most standard ADME/Tox assays that require access to both apical and basal compartments incompatible.

To overcome existing limitations of the current *in vitro* systems, a proprietary bioprinting platform was utilized to develop a multicellular 3D primary human intestinal tissue model to better mimic native tissue structure and function ([@bib43], [@bib42]). The fully human primary cell-derived tissue designed with laminar architecture incorporates a polarized intestinal epithelium supported by an interstitial tissue layer allowing compatibility with standard histological and biochemical ADME/Tox readouts. Tissues maintained viability over 2 weeks in culture, developed barrier function, and demonstrated selective permeability. Presence of functional key CYP450 metabolic enzymes and transporters was confirmed with endogenous expression similar to native intestine. Last, tissue injury was evaluated in response to known toxicants indomethacin and tumor necrosis factor alpha (TNF-α) revealing barrier disruption and cytotoxicity at the biochemical and histological levels. The human tissue combined with the reproducibility of the automated 3D bioprinting platform and compatibility with standard assay approaches make this system a practical *in vitro* tool for ADME/Tox applications across drug development.

Results {#sec2}
=======

Histological Characterization of 3D Human Intestinal Tissue {#sec2.1}
-----------------------------------------------------------

The Organovo 3D NovoGen Bioprinter system was used to create an *in vitro* model of the human intestine. The tissue was generated with bilayered architecture, consisting of a human intestinal myofibroblast (IMF) interstitium supporting an epithelial layer containing human intestinal epithelial cells (hIEC) and maintained up to 21 days in culture. Tissues were printed on cell culture inserts ([Figure 1](#fig1){ref-type="fig"}A) allowing access to both apical and basolateral surfaces for direct compound testing. Histological analysis at day 17 showed that tissues exhibited polarized columnar epithelial morphology and secondary structure formation ([Figures 1](#fig1){ref-type="fig"}B--1I). The epithelial and interstitial tissue compartments are in direct contact with each other but remained distinct, with correct expression of epithelial (CK19) and myofibroblast (vimentin) cell-specific markers ([Figure 1](#fig1){ref-type="fig"}C). E-cadherin and ZO-1, key proteins involved in tight junction formation and barrier function, were expressed between epithelial cells of the hIEC layer ([Figure 1](#fig1){ref-type="fig"}D). Correct polarization of the hIEC and brush border formation were seen by positive staining for brush border protein villin at the apical surface ([Figure 1](#fig1){ref-type="fig"}E). Periodic acid-Schiff (PAS)/Alcian blue staining confirmed an apical brush border and suggested the presence of a subpopulation of goblet cells as well as the excretion of mucus ([Figure 1](#fig1){ref-type="fig"}F). Immunohistochemistry for mucin-2 confirmed the presence of goblet cells and mucous secretion ([Figure 1](#fig1){ref-type="fig"}G), a feature similar to native tissue and an indication of normal intestinal function. In addition to goblet cells, other specialized cell types present in the intestinal epithelium included lysozyme-positive Paneth cells and chromogranin-expressing enteroendocrine cells ([Figures 1](#fig1){ref-type="fig"}H and 1I). Patterning of 3D intestinal tissues was similar to that observed in native intestinal tissue and consistent between multiple donors ([Figure S1](#mmc1){ref-type="supplementary-material"}). Tissue architecture of the 3D intestinal model was also compared with that of standard Caco-2 monolayer culture ([Figure S2](#mmc1){ref-type="supplementary-material"}). Caco-2 monolayers achieved a polarized epithelial phenotype with tight junction formation, although epithelial morphology appeared less columnar and lacked secondary structure formation. Subpopulations of specialized cells and evidence of mucus production were also absent in Caco-2 monolayers ([Figure S2](#mmc1){ref-type="supplementary-material"}). Substitution of hIEC with Caco-2 cells in the 3D bioprinted model produced a bilayered structure with increased thickening of the epithelial layer and cyst formation over time, akin to the cancer origin ([Figure S3](#mmc1){ref-type="supplementary-material"}A). However, this phenotype change did not improve transporter or enzyme gene expression to the level of 3D intestinal tissues fabricated with primary hIECs ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Thus the standard Caco-2 monolayer was used as the main comparison to bioprinted tissues composed of primary hIECs.Figure 1Architecture of 3D Intestinal Tissue(A) A bilayered architecture is achieved by bioprinting an interstitial layer containing adult human intestinal myofibroblasts (IMF) followed by adult human intestinal epithelial cells (hIEC). The vimentin-expressing interstitial cells and CK19-expressing epithelial compartments remain separate over 17 days in culture (B, C). Epithelial cells express markers necessary for barrier formation such as E-cadherin (D), ZO-1 (D, inset), and apically expressed villin (E). Mucus production from goblet cells (\* denotes secreted mucus, arrow indicates goblet cells) is observed throughout culture (F, G). Lysozyme-stained Paneth cells (H) and chromogranin-expressing enteroendocrine cells (I) are also present.

Characterization of Gene Expression {#sec2.2}
-----------------------------------

Gene expression analysis was utilized to further evaluate the expression of key intestinal epithelial tissue markers, metabolic enzymes, and transporters in the 3D intestinal tissue and was compared with both native donor intestinal tissue and standard Caco-2 monolayers ([Figure 2](#fig2){ref-type="fig"}). Although five native donor tissues were processed, challenges in obtaining high-quality donor material resulted in the utilization of three of five donors for gene expression analysis. To specifically study differential expression in the epithelium and to remove any variance in the total cell number, genes were analyzed relative to the expression of epithelial-specific marker CK19. Heatmap visualization shows close clustering of 3D intestine to the native intestine compared with more disparate Caco-2 monolayers ([Figure 2](#fig2){ref-type="fig"}A). In support of histological findings, tight junction marker E-cadherin *(CDH1)* and brush border marker villin (*VIL1*) were highly expressed, as well as markers for specialized cell subpopulations including Paneth cells (*LYZ*), enteroendocrine cells (*CHGA*), and goblet cells (*MUC2*) ([Figure 2](#fig2){ref-type="fig"}B). Key xenobiotic-activated nuclear receptors involved in drug metabolism and disposition including *VDR, PXR (NR1I2)*, and *CXR (NR1I3)* were expressed in 3D intestinal tissue at comparable levels to native intestine. Major intestinal Phase I CYP450 metabolic enzymes including *CYP3A4*, *CYP2C9, CYP2C19, CYP2D6,* and *CYP2J2* were also detected. Clinically important *CYP3A4* was highly expressed in the 3D intestinal model, whereas it was notably not detectable in Caco-2 monolayers ([Figure 2](#fig2){ref-type="fig"}B). Key intestinal Phase II metabolic enzymes *GSTP1* and *UGT1A1* were expressed, as well as regulators of fatty acid metabolism, including *DGAT1, MOGAT2*, and *MTTP*. Major efflux transporters *P-gp (ABCB1, MDR1)* and *BCRP (ABCG2)*, key uptake transporters *PEPT1 (SLC15A1)* and *OATP2B1 (SLCO2B1)*, and intestinal bile acid-related transporters *ASBT (SLC10A2), OSTa (SLC51A),* and *OSTb (SLC51B)* were expressed in 3D intestinal tissues with levels comparable with those in native intestine ([Figure 2](#fig2){ref-type="fig"}B). Collectively, gene expression levels in 3D intestinal tissues corresponded to endogenous levels observed in native tissue, whereas Caco-2 monolayers exhibited reduced, overexpressed, or absent expression of several genes suggesting that the bioprinted model more closely resembles native tissue.Figure 2Gene Expression Comparisons of Native Intestine, 3D Intestinal Tissue, and Caco-2 Monolayers(A) Heatmap clustering shows a closer relationship between native intestine and 3D intestinal tissue than Caco-2 monolayers (native intestine N = 3 donors, 3D intestine n = 3 biological replicates per donor, and Caco-2, n = 3 biological replicates).(B) General markers for intestinal barrier function (*CDH1, VIL1*) are similar among the three groups. Epithelial subtype markers are highest for native and 3D intestinal tissue. Drug-inducible transcription factor *NR1I2* (*PXR*) is similar for native intestine and 3D intestinal tissue. Native intestine and 3D intestinal tissue express all metabolic enzymes analyzed, including Phase I cytochrome P450s, the majority of which Caco-2 cells lack. Transporters are expressed by all three groups, with variation in the level. For efflux transporters, 3D intestine is most similar to native intestine, whereas Caco-2 cells underexpress *ABCB1* (*P-gp*) and *ABCG2* (*BCRP*). Uptake transporters *SLC15A1* (*PEPT1*) and *SLCO2B1* (*OATP2B1*) are similarly expressed by native and 3D intestine, but not by Caco-2 monolayers. Data in (B) are expressed as mean ± SD.

Demonstration of Cytochrome P450 Metabolic Function in 3D Intestinal Tissue {#sec2.3}
---------------------------------------------------------------------------

Functional assays were performed to evaluate the activity and specificity of CYP3A4 and CYP2C9, two major intestinal Phase I cytochrome P450 metabolic enzymes profiled in gene expression studies ([Figure 3](#fig3){ref-type="fig"}). CYP2C9 activity was readily detected in 3D intestinal tissue by luminogenic P450 substrate conversion and could be significantly inhibited by sulfaphenazole ([Figure 3](#fig3){ref-type="fig"}A). CYP3A4 activity and specific inhibition by ketoconazole were confirmed by both a luminogenic P450 substrate conversion ([Figure 3](#fig3){ref-type="fig"}B) and midazolam metabolite formation ([Figures 3](#fig3){ref-type="fig"}D and 3E). Luminogenic substrate conversion occurred at a higher level in 3D intestine compared with Caco-2 monolayers ([Figure 3](#fig3){ref-type="fig"}C), and only 3D tissues were induced by rifampicin treatment ([Figures 3](#fig3){ref-type="fig"}C and 3E). Rifampicin treatment was associated with significantly higher turnover of CYP3A substrates in treated tissues and significant upregulation of PXR-inducible genes including *CYP2C9, CYP3A4, CYP3A5, P-gp*, and *UGT1A1* ([Figures 3](#fig3){ref-type="fig"}E and 3F). Variation in human CYP3A-dependent metabolism is well established ([@bib19]). Comparison of CYP3A4 activity by midazolam turnover for 3D intestinal tissues fabricated from three separate donors showed expected interindividual donor variation (Donor 1: 19.3 ± 1.9; Donor 2: 2.85 ± 0.59; Donor 3: 3.6 ± 3.6 pmol/min/mg) consistent with gene expression data ([Figure 2](#fig2){ref-type="fig"}A) as well as demonstrated reproducibility of ketoconazole inhibition and rifampicin induction between donors ([Table S1](#mmc1){ref-type="supplementary-material"}). The degree of variability in CYP3A4 activity was consistent with observations of native intestine gene expression in the current study (6.3-fold among donors, [Figure 2](#fig2){ref-type="fig"}A) and with previous studies evaluating intestinal CYP3A4 activity (18-fold among donors) ([@bib19]).Figure 3Cytochrome P450 Metabolism in 3D Intestinal Tissue(A) CYP2C9 basal activity was validated by a luciferin activity assay and was reduced by inhibitor sulfaphenazole (n = 6). CYP3A4 activity was shown by luciferin activity assay (n = 3--4) (B, C) and midazolam hydroxylation (n = 5) (D, E), both of which were inhibited by ketoconazole. (C, E) CYP3A4 induction via rifampicin treatment was detected by increased luciferin activity and midazolam metabolism in 3D intestine (n = 5). (C) A comparison of CYP3A4 activity in 3D intestinal tissue with 2D Caco-2 monolayer shows low activity of CYP3A4 in Caco-2 monolayers with no rifampicin induction (n = 4--11 for 3D intestine, n = 3 for 2D Caco-2). (F) Rifampicin treatment increased gene expression of PXR-regulated CYPs, *ABCB1* (*P-gp*), and *UGT1A1* but not *CK19* and *ECAD* (n = 4). Level of significance: \*\*\*\*p \< 0.0001, \*\*\*p \< 0.001, \*\*p \< 0.01 by two-way ANOVA. Data are expressed as mean ± SD.

Demonstration of Barrier Function {#sec2.4}
---------------------------------

The intestine is a selectively permeable barrier, regulating absorption of both nutrients and xenobiotics. TEER was utilized to measure barrier function in 3D intestinal tissues over a 21-day culture period. Measurements demonstrated that the tissues developed and maintained barrier function between days 10 and 21 of culture, exhibiting values within a physiological range (50--100 Ω\*cm^2^) comparable to native human intestine ([@bib28]) ([Figure 4](#fig4){ref-type="fig"}A). Representative compounds with high and low permeability were used to further validate 3D intestinal tissue barrier function ([Figure 4](#fig4){ref-type="fig"}B, [Table S2](#mmc1){ref-type="supplementary-material"}). Paracellular transport marker lucifer yellow correctly demonstrated low permeability in 3D intestine (P~app~ = 0.45 ± 1.5 × 10^6^ cm/s), suggesting the presence of an intact physical barrier for drug transport. The 3D intestinal tissues correctly distinguished between low-, intermediate-, and high-permeability compounds. Mitoxantrone (P~app~ = 0.2 ± 0.03 × 10^6^ cm/s) is a low-permeability compound with absorption mainly mediated by ABCG2 (BCRP) efflux transporter. Topotecan and digoxin showed P~app~ values in the intermediate range (3.1 ± 0.63 × 10^6^ cm/s and 8.53 ± 2.02 × 10^6^ cm/s, respectively), whereas propranolol, a passive transcellular transport reference compound, showed the highest permeability (P~app~ = 14.8 ± 1.96 × 10^6^ cm/s).Figure 4Barrier Function of 3D Intestinal Tissue(A) Transepithelial electrical resistance (TEER) was measured for 3D intestinal tissue from day 6 to day 21, showing increase early in culture, with maintenance of barrier function within physiological levels (dotted lines) after day 10 (n = 24).(B) Permeability of test compounds for 3D intestine, measured in the apical to basal direction, shows distinction between low- (mitoxantrone \[n = 4\]), moderate- (topotecan \[n = 4\], digoxin \[n = 6\]), and high- (propranolol \[n = 5\]) permeability compounds.(C) Comparison of TEER values shows more physiological TEER values for 3D intestine (n = 24) and 3D Caco-2 (n = 6) versus 2D Caco-2 (n = 5), whereas IMF alone does not show barrier function (n = 19).(D) Comparison of lucifer yellow permeability values between models shows low permeability for all epithelial-cell-containing models and high permeability for IMF only (n = 4 for 2D and 3D Caco-2 and IMF only, n = 28 for 3D intestine). Data are expressed as mean ± SD.

In comparison, Caco-2 monolayers demonstrated significantly higher TEER measurements (840 ± 55 Ω\*cm^2^) ([Figure 4](#fig4){ref-type="fig"}C). When substituted for hIEC in the 3D bioprinted model, 3D Caco-2 tissues had reduced TEER (254 ± 45 Ω\*cm^2^) compared with their 2D counterparts, a possible effect of cyst-like secondary structure formation, but the values remained above a physiological range. Both 2D and 3D Caco-2 models had low lucifer yellow permeability (P~app~ = 0.46 ± 0.25 × 10^6^ cm/s and 1.05 ± 0.1 × 10^6^ cm/s, respectively) confirming barrier formation, whereas IMF tissue alone did not show barrier function (5 ± 3 Ω\*cm^2^) and exhibited high permeability (163 ± 29 × 10^6^ cm/s) ([Figure 4](#fig4){ref-type="fig"}D).

Transporter Localization and Function in 3D Intestinal Tissue Model {#sec2.5}
-------------------------------------------------------------------

Intestinal efflux and uptake transporters can be both sites of drug-drug interactions and limiting factors for drug absorption. Immunohistochemical staining confirmed the correct polarized epithelial expression of key efflux transporters at the apical (P-gp \[ABCB1\], BCRP \[ABCG2\], MRP2 \[ABCC2\]) and basolateral (MRP3 \[ABCC3\]) surfaces in a continuous pattern similar to native intestine ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S4](#mmc1){ref-type="supplementary-material"}). To assess the capability of 3D intestinal tissues to predict active efflux, P-gp and BCRP function were evaluated by measuring bidirectional transport with and without inhibition ([Figures 5](#fig5){ref-type="fig"}C and 5D). Under control conditions, asymmetric permeability of P-gp substrate digoxin was observed with an efflux ratio greater than 2. Inhibition of P-gp by zosuquidar ([@bib9]) decreased the rate of B to A transport, reducing the efflux ratio to 1.2, to confirm the activity of P-gp. BCRP function was tested by efflux of topotecan ([Figure 5](#fig5){ref-type="fig"}D) and mitoxantrone ([Figure S5](#mmc1){ref-type="supplementary-material"}). BCRP/P-gp substrate topotecan and BCRP substrate mitoxantrone were preferentially transported in the B to A direction with efflux ratios of 8.8 and 190, respectively. Furthermore, subsequent inhibition of topotecan transport by the BCRP inhibitor Ko143 ([@bib1]) reduced the efflux ratio to 3.6 and dual inhibition with Ko143 and zosuquidar further decreased the efflux ratio to 1.4. Collectively, these results demonstrate that the 3D intestinal tissue model expresses clinically relevant P-gp and BCRP transporters with proper localization and function. Compounds assessed demonstrate greater efflux ratio similarity to other models composed of primary human intestinal cells than to Caco-2 models ([Table S3](#mmc1){ref-type="supplementary-material"}). Histological analysis showed apical P-gp and BCRP expression in patches across Caco-2 monolayers, whereas MRP2 and MRP3 appeared to be overexpressed ([Figures 5](#fig5){ref-type="fig"}A, 5B, and [S4](#mmc1){ref-type="supplementary-material"}). Transporter expression patterning was not rescued by substitution of Caco-2 cells into the 3D bioprinted model ([Figure S3](#mmc1){ref-type="supplementary-material"}).Figure 5P-gp and BCRP Transporter Function in 3D Intestinal Tissue(A and B) (A) P-gp and (B) BCRP are apically localized in 3D intestinal tissue, similar to native intestine. Expression in Caco-2 monolayers was in patches at the apical surface.(C) P-gp substrate digoxin had greater permeability in the B to A direction with efflux ratio of 2.1. In the presence of P-gp inhibitor zosuquidar, the efflux ratio of digoxin reduced to 1.2 (n = 6).(D) BCRP/P-gp substrate topotecan had an efflux ratio of 8.8 under control conditions. BCRP inhibition by Ko143 reduced B to A transport and the efflux ratio decreased to 3.6. Dual inhibition of P-gp and BCRP resulted in ablation of transport with an efflux ratio of 1.4 (n = 3--4). Level of significance: \*\*\*\*p \< 0.0001 by two-way ANOVA. Data in (C) and (D) are expressed as mean ± SD.

Characterization of 3D Intestinal Tissues as a Model for Gastrointestinal Toxicity {#sec2.6}
----------------------------------------------------------------------------------

The utility of the 3D intestinal model for compound toxicity applications was evaluated by the NSAID indomethacin, a prostaglandin E~2~ (PGE2) oxygenase inhibitor and known gastrointestinal (GI) toxicant that can reduce intestinal epithelial barrier function through enterocyte apoptosis and necrosis ([@bib5]). The 3D intestinal tissue showed a dose-dependent decrease in barrier function as measured by TEER in response to 24-hr indomethacin treatment ([Figure 6](#fig6){ref-type="fig"}A). Injury to the intestinal cells was detected by lactate dehydrogenase (LDH) release and was significantly increased in the presence of indomethacin doses above 0.25 mM ([Figure 6](#fig6){ref-type="fig"}B), consistent with previous reports modeling indomethacin injury *in vitro* ([@bib31]). All doses of indomethacin demonstrated inhibition of prostaglandin E~2~ secretion, confirming the known mechanism of activity ([Figure 6](#fig6){ref-type="fig"}C). Histological analysis further illustrated dose-dependent disruption of epithelial morphology with decreased E-cadherin expression, consistent with loss in barrier function ([Figure 6](#fig6){ref-type="fig"}D). Release of inflammatory cytokines may also damage the intestine, and TNF-α is a major contributor to disease-related inflammation and intestinal toxicity ([@bib18], [@bib21]). To evaluate the susceptibility of the model to pro-inflammatory cytokines, tissues were dosed with TNF-α for 24 hr and evaluated for changes in morphology, LDH release, and gene expression ([Figure 7](#fig7){ref-type="fig"}). TNF-α altered the epithelial morphology and resulted in the dissociation of cells from the interstitial layer accompanied by a significant increase in LDH release, suggesting a cytotoxic response and enterocyte death. Gene expression for several known targets of the TNF-α/nuclear factor (NF)-κB pathway including interleukin (*IL)-6*, *IL-8*, *CCL2, CXCL10, ICAM1,* and *TNF-α* were upregulated, demonstrating activation of an inflammatory cascade ([Figure 7](#fig7){ref-type="fig"}C) in response to tissue injury.Figure 6Indomethacin Toxicity in 3D Intestinal Tissue(A) TEER measurements of tissues following 24-hr incubation with ethanol vehicle or varying doses of indomethacin show dose response decrease in TEER with increasing indomethacin.(B) LDH activity increased with increasing indomethacin dose, suggesting increased cytotoxicity.(C) Prostaglandin E~2~ synthesis decreased to similar levels for all indomethacin doses tested, confirming drug activity (n = 6--7, A--C).(D) Histology of indomethacin-treated tissues shows disruption of the epithelium and distorted nuclear staining at higher doses of indomethacin, accompanied by a reduction in E-cadherin, a marker of barrier function. Level of significance: \*\*\*\*p \< 0.0001 by one-way ANOVA. Data in (A--C) are expressed as mean ± SD.Figure 7TNF-α-Induced Toxicity in 3D Intestinal Tissue(A) Tissues treated with TNF-α for 24 hr showed increased epithelial disorganization compared with controls.(B) Increased LDH activity correlated with changes in cell morphology following TNF-α treatment (n = 5--6).(C) A subset of genes related to inflammation, *TNF-α, IL-6, IL-8, CCL2,* and *ICAM,* were upregulated in response to TNF-α treatment (n = 3). Level of significance: \*\*\*p \< 0.001 by t test in (B); \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001 by two-way ANOVA in (C). Data in (B) and (C) are expressed as mean ± SD.

Discussion {#sec3}
==========

Current preclinical models are limited in the ability to capture complexities and function of human intestinal tissue, which can lead to poor predictability in drug development ([@bib2], [@bib3], [@bib5], [@bib11], [@bib20]). This study incorporated primary cells into a fully human 3D bioprinted intestinal tissue model to recapitulate multiple facets of native intestinal biology and function *in vitro*. Histological analysis of the 3D intestinal tissues confirmed development and maintenance of a polarized epithelium with columnar epithelial morphology, tight junctions, and apical brush border formation. Stability of tissue architecture and function for greater than 2 weeks in culture suggests that the model may be suitable for extended compound studies.

In this study, the 3D intestinal model was compared with Caco-2 cells cultured as a standard 2D monolayer with results suggesting that the 3D tissues more closely mimic native tissue in gene and protein expression patterning and function. The divergence of Caco-2 cells from native tissue, consistent with previous reports ([@bib22], [@bib29]), may be due in part to their cancer origin and variability in expression patterns of metabolic enzymes and transporters along the GI tract ([@bib19], [@bib20]). Both native donor tissue and the 3D intestinal model were derived from the ileum, whereas Caco-2 cells are derived from the colon. Substitution of primary intestinal epithelial cells with Caco-2 cells in the 3D system produced phenotypes more consistent with native tissue, including secondary structure formation, indicating a benefit to the 3D microenvironment that may be in part influenced by cross talk with interstitial cells, but did not rescue aberrant expression patterning.

Histology and gene expression analyses demonstrated the presence of specialized cell subpopulations in 3D intestinal tissues that are notably absent in cell lines including the Caco-2 model. The presence of mucin-2-expressing goblet cells, evidence of mucus production, and lysozyme-expressing Paneth cells suggests the potential for modeling mucosal barrier function and antimicrobial or microbiome function. Chromogranin-positive cells suggest the potential to study enteroendocrine function in the gut, including glucagon-like peptide (GLP)-1 signaling. Cell subpopulations indicate that primary cells in 3D intestinal tissues may be able to undergo directed differentiation by modification of culture conditions similar to maturation observed in organoid cell culture ([@bib23], [@bib27], [@bib39]). Incorporation of induced pluripotent stem cells may be considered as an alternative cell source to primary cells, although maturity can resemble a fetal stage phenotype ([@bib26]) with inconsistent barrier function over time ([@bib12]).

The 3D intestinal tissue demonstrated the expression and function of key enzymes involved in xenobiotic metabolism including CYP3A4, an enzyme known to be absent in Caco-2 models ([@bib38]), consistent with our findings. Enzyme activity was confirmed by modulation of midazolam hydroxylation through both inhibition and induction---CYP3A4 activity and PXR-regulated genes were induced in response to rifampicin. The 3D intestinal model demonstrated reproducible midazolam metabolism in tissues separately fabricated from three different donors with interindividual donor variation as expected ([@bib19]). Values were similar to those shown for intestinal slices ([@bib34]) and much higher than those reported for 2D systems ([@bib29], [@bib38]), suggesting suitability of this model for drug-induced metabolic and transporter studies, which cannot be achieved by previous primary or Caco-2 models ([@bib29], [@bib38]).

A differentiating factor of this 3D model over other 3D primary cell systems including organoids and more recent cell-seeded tubular scaffolds ([@bib6]) is the laminar architecture that provides both apical and basal access and compatibility with standard barrier function and directional transport assays. Physiological barrier function was successfully demonstrated by TEER (74.4 ± 24.5 Ω\*cm^2^) in 3D intestinal tissues at day 10 and maintained through day 21 of culture. Furthermore, tissues could successfully differentiate between low-, intermediate-, and high-permeability substrates such as paracellular marker lucifer yellow and transcellular marker propranolol. With the advantage of physiological TEER values, models with hIECs may yield a better correlation with *in vivo* permeability compared with Caco-2 monolayers with artificially high measurements (840 ± 55 Ω\*cm2), which may be due in part to observed differences in E-cadherin expression ([@bib28]). Barrier measurements in the 3D intestinal model were consistent with reported monolayer cultures of adult intestinal epithelial cells (70--120 Ω\*cm^2^) ([@bib30]). These monolayer models, however, are typically limited to \<11 days in culture, can suffer from low CYP expression similar to Caco-2 cells, and have not yet been assessed for toxicity or inflammatory response ([@bib12], [@bib29], [@bib30]).

Intestinal efflux and influx transporters are key mediators of absorption for low-permeability drugs. Clinically relevant P-gp and BCRP efflux transporters, which can significantly affect the net fraction of compound absorbed ([@bib4], [@bib20]), were correctly expressed in the apical epithelium and functional in response to known substrates digoxin and topotecan, respectively. The level of efflux in the 3D intestinal tissue model was more similar to that previously observed in 2D human intestinal cell monolayers than with Caco-2 monolayers ([@bib12], [@bib15], [@bib29]). Expression of functional transporters suggests that this system could be applied to assess the relative contributions of efflux transporters to drug disposition, or could be used as a potential model for increased absorption by targeting uptake transporters such as PEPT1 and OATP2B1. The dual presence of transporters and enzymes in the 3D intestinal tissue model suggests that it could be used to shed light on complex drug-drug interactions, such as those seen with overlapping P-gp/CYP3A4 substrates ([@bib14]). Furthermore, high expression of enzymes involved in fatty acid metabolism in the 3D intestinal tissue indicates a potential application for evaluating compounds targeting these enzymes to combat obesity ([@bib25]).

GI toxicity is a common clinical adverse event that cannot be accurately predicted or characterized with current *in vitro* or *in vivo* models ([@bib3], [@bib5], [@bib21]). The NSAID indomethacin demonstrated a toxicity response in 3D intestinal tissue with a dose-dependent decrease in barrier function by TEER and corresponding epithelial cell disruption, correlating with previously reported *in vitro* ([@bib31], [@bib32]) and *in vivo* outcomes ([@bib5]). The 3D intestinal tissue also responded to the toxic inflammatory stimulus TNF-α, resulting in epithelial cell death and upregulation of inflammatory genes, consistent with human data ([@bib7]) and previous Caco-2 studies ([@bib8], [@bib33]). These data combined with long-term viability suggest that the 3D intestinal model may be applied to characterize other known classes of compounds that have off-target toxicity in the intestine, such as chemotherapeutics ([@bib3]), to evaluate inflammatory pathways, and to model chronic diseases, such as inflammatory bowel disease (IBD), Crohn disease, and colitis ([@bib3], [@bib5], [@bib21]). Future applications could increase complexity by incorporating additional cell types such as immune cells or cancer cells, and by utilizing healthy and diseased donor material ([@bib10], [@bib35]), to better understand the contribution of each cell type to the disease phenotype and to better characterize candidate modulators for therapeutic intervention on disease-relevant backgrounds.

In conclusion, we provide evidence for a fully human 3D intestinal tissue model composed of primary cells with increased complexity and function compared with standard *in vitro* models. The 3D tissue recapitulates major intestinal features and physiological functions and is designed to provide a flexible platform compatible with barrier function, permeability, metabolism, transport, and toxicity studies.

Methods {#sec4}
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